NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-03. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Peer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factThe New England Journal of Medicine published Phase 1/2 trial data for Revolution Medicines' RASONQUE (daraxonrasib). |
| What else was confirmed? | Reported factThe trial evaluated previously treated RAS mutant non-small cell lung cancer. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for RVMD yet — this is the next research task. |
| What would change the assessment? | UnknownRVMD equity volume and institutional price target revisions — Track post-market trading volume and biotech specialist sell-side model revisions following NEJM publication. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · The New England Journal of Medicine published Phase 1/2 trial data for Revolution Medicines' RASONQUE (daraxonrasib).
- · The trial evaluated previously treated RAS mutant non-small cell lung cancer.
- · Results showed a 42% objective response rate and 16.0 months median overall survival.
Public research record
Research framework · page evidenceCompleted event assessment
clinical pipeline de-risking following peer-reviewed NEJM publication
| Type | Claim | Scope |
|---|---|---|
| Assumption | The New England Journal of Medicine published Phase 1/2 trial data for Revolution Medicines' RASONQUE (daraxonrasib). | 2026-09-03 |
| Interpretation | clinical pipeline de-risking following peer-reviewed NEJM publication | RVMD |
Countercase, invalidators, and sources
Late-stage pivotal trials replicate the 42% ORR, establishing daraxonrasib as a standard of care in RAS mutant lung cancer.
- · RVMD equity volume and institutional price target revisions — Track post-market trading volume and biotech specialist sell-side model revisions following NEJM publication.
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer · 2026-09-02
What remains unresolved
- Base path
- RVMD receives favorable analyst revisions while initiating phase 3 enrollment protocols.
- Adverse path
- Subsequent safety or durability concerns emerge in larger patient cohorts, tempering initial phase 1/2 enthusiasm.
- Supportive path
- Late-stage pivotal trials replicate the 42% ORR, establishing daraxonrasib as a standard of care in RAS mutant lung cancer.
- · RVMD equity volume and institutional price target revisions — Track post-market trading volume and biotech specialist sell-side model revisions following NEJM publication.today
Evidence
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer2026-09-02
“Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival”
Supports: NEJM published Phase 1/2 data on RASONQUE showing 42% ORR and 16.0 months median OS in RAS mutant NSCLC.